…
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Quidel Corporation makes rapid diagnostic tests and instruments for point-of-care and clinical laboratories, covering antigen, molecular and immunoassay platforms. Long-term growth drivers include greater adoption of decentralized testing, recurring consumable revenue, expansion of respiratory and multiplex assays and international market penetration, which may appeal to investors seeking exposure to diagnostics' recurring-revenue streams.
Principal risks are revenue volatility as COVID-era testing demand normalizes, regulatory and reimbursement shifts, intense competition from larger diagnostics firms and supply-chain or manufacturing disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1107.70M | -2131.50M | -29.10M | 735.90M | 900.36M |
| Net income | -1131.80M | -2052.00M | -10.10M | 548.70M | 704.23M |
| Selling general administrative | 746.30M | 760.60M | 748.10M | 621.00M | 84.25M |
| Selling and marketing expenses | - | 6.20M | 15.10M | - | 175.32M |
| Gross profit | 1274.20M | 1286.50M | 1497.10M | 1936.00M | 1270.89M |
| Reconciled depreciation | 442.00M | 453.40M | 457.20M | 132.50M | 54.38M |
| Ebit | -930.10M | -1943.20M | 149.80M | 843.70M | 906.07M |
| Ebitda | -488.10M | -1489.80M | 607.00M | 1104.10M | 915.62M |
| Depreciation and amortization | 442.00M | 453.40M | 457.20M | 260.40M | 9.56M |
| Non operating income net other | - | - | - | - | -5.71M |
| Operating income | -919.20M | -1960.90M | 139.10M | 843.70M | 906.07M |
| Other operating expenses | 3649.40M | 4743.80M | 2858.70M | 2286.30M | 782.93M |
| Interest expense | 177.60M | 188.30M | 178.90M | 75.70M | 5.71M |
| Tax provision | 24.10M | -79.50M | -19.00M | 187.20M | 196.13M |
| Interest income | 2.20M | 2.60M | 5.50M | 1.30M | - |
| Net interest income | -185.60M | -188.90M | -176.70M | -75.70M | -5.71M |
| Non recurring | - | - | - | - | -9.56M |
| Income tax expense | 24.10M | -79.50M | -19.00M | 187.20M | 196.13M |
| Total revenue | 2730.20M | 2782.90M | 2997.80M | 3266.00M | 1698.55M |
| Total operating expenses | 2193.40M | 3247.40M | 1358.00M | 956.30M | 355.27M |
| Cost of revenue | 1456.00M | 1496.40M | 1500.70M | 1330.00M | 427.66M |
| Total other income expense net | -188.50M | -170.60M | -168.20M | -107.80M | -5.71M |
| Net income from continuing ops | -1131.80M | -2052.00M | -10.10M | 548.70M | 704.23M |
| Net income applicable to common shares | - | - | - | 548.70M | 704.23M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5769.30M | 6423.60M | 8563.10M | 8855.80M | 2430.37M |
| Intangible assets | 2563.80M | 2735.60M | 2934.30M | 3123.80M | 98.66M |
| Other current assets | 250.50M | 135.60M | 77.00M | 252.10M | 4.59M |
| Total liab | 3848.80M | 3439.10M | 3557.20M | 3921.20M | 501.01M |
| Total stockholder equity | 1920.50M | 2984.50M | 5005.90M | 4934.60M | 1929.36M |
| Deferred long term liab | - | - | - | 3.50M | 36.49M |
| Other current liab | 429.80M | 341.00M | 335.70M | 439.80M | 210.07M |
| Common stock | 0.10M | 0.10M | 0.10M | - | 0.04M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.00M | 0.04M |
| Retained earnings | -996.00M | 135.80M | 2187.80M | 2197.90M | 1649.20M |
| Other liab | - | - | - | 294.90M | 48.58M |
| Good will | 0.00M | 649.50M | 2492.00M | 2476.80M | 337.02M |
| Other assets | - | - | - | 395.80M | 39.71M |
| Cash | 169.80M | 98.30M | 118.90M | 292.90M | 802.75M |
| Total current liabilities | 966.10M | 998.80M | 833.80M | 1007.00M | 323.52M |
| Current deferred revenue | 37.80M | 33.50M | 36.80M | 76.40M | 1.92M |
| Net debt | 2664.10M | 2583.10M | 2495.20M | 2531.80M | -664.16M |
| Short term debt | 207.60M | 372.90M | 166.50M | 207.50M | 10.04M |
| Short long term debt | 178.30M | 341.80M | 139.80M | 207.50M | - |
| Short long term debt total | 2833.90M | 2681.40M | 2614.10M | 2824.70M | 138.59M |
| Other stockholder equity | 2931.80M | 2884.80M | 2848.00M | 2804.30M | 279.77M |
| Property plant equipment | - | - | - | 1520.00M | 349.20M |
| Total current assets | 1447.30M | 1218.90M | 1310.50M | 1575.10M | 1440.31M |
| Long term investments | - | 0.00M | 7.40M | 21.00M | 37.85M |
| Net tangible assets | - | - | - | -666.00M | 1622.24M |
| Short term investments | 32.40M | 48.40M | 48.40M | 52.10M | 25.76M |
| Net receivables | 417.00M | 451.30M | 488.40M | 453.90M | 393.85M |
| Long term debt | 2471.90M | 2141.30M | 2274.80M | 2430.80M | - |
| Inventory | 577.60M | 533.70M | 577.80M | 524.10M | 198.76M |
| Accounts payable | 279.40M | 246.00M | 294.80M | 283.30M | 101.49M |
| Accumulated other comprehensive income | -15.40M | -36.20M | -30.00M | -67.60M | 0.35M |
| Common stock total equity | - | - | - | - | 0.04M |
| Retained earnings total equity | - | - | - | - | 1649.20M |
| Non currrent assets other | 244.40M | 249.00M | 179.00M | 122.70M | 19.62M |
| Non current assets total | 4322.00M | 5204.70M | 7252.60M | 7280.70M | 990.06M |
| Capital lease obligations | 183.70M | 198.30M | 199.50M | 186.40M | 138.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -149.90M | -187.60M | -1644.20M | -63.69M |
| Change to liabilities | - | - | - | 23.50M | -23.34M |
| Total cashflows from investing activities | -192.70M | -149.90M | - | -1644.20M | -319.53M |
| Net borrowings | 155.10M | 53.40M | - | 346.20M | -0.26M |
| Total cash from financing activities | 155.80M | 48.80M | -265.80M | 252.00M | -173.18M |
| Change to operating activities | - | - | - | -83.20M | 19.65M |
| Net income | -1131.80M | -2052.00M | -10.10M | 548.70M | 704.23M |
| Change in cash | 71.30M | -21.00M | -174.00M | -508.90M | 312.81M |
| Begin period cash flow | 98.50M | 119.50M | 292.90M | 802.80M | 489.94M |
| End period cash flow | 169.80M | 98.50M | 118.90M | 293.90M | 802.75M |
| Total cash from operating activities | 105.20M | 83.00M | 280.20M | 885.30M | 805.87M |
| Issuance of capital stock | 6.10M | 5.00M | 11.60M | 26.40M | 7.55M |
| Depreciation | 442.00M | 453.40M | 457.20M | 283.60M | 54.38M |
| Other cashflows from investing activities | -11.00M | -10.70M | - | 18.40M | 36.88M |
| Change to inventory | -148.30M | -134.10M | -211.60M | -116.90M | -85.04M |
| Change to account receivables | -117.50M | 5.40M | 160.00M | 150.20M | 118.85M |
| Sale purchase of stock | 0.00M | -9.60M | -7.20M | -74.30M | -103.44M |
| Other cashflows from financing activities | -5.40M | -9.60M | -43.80M | 2688.20M | -77.03M |
| Change to netincome | - | - | - | 106.20M | 50.08M |
| Capital expenditures | 188.20M | 195.10M | 209.30M | 140.90M | 292.72M |
| Change receivables | - | - | - | - | 118.85M |
| Cash flows other operating | - | - | - | - | -13.70M |
| Cash and cash equivalents changes | - | - | - | - | 313.16M |
| Change in working capital | -125.80M | -158.70M | -194.90M | -53.20M | -2.78M |
| Stock based compensation | 45.90M | 42.10M | 51.60M | 48.40M | 25.40M |
| Other non cash items | 868.60M | 1897.50M | -72.20M | 57.80M | -0.04M |
| Free cash flow | -83.00M | -112.10M | 70.90M | 744.40M | 513.14M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| QDEL QuidelOrtho Corp |
-0.03 0.23% |
10.68 | - | 7.23 | 0.27 | 0.43 | 1.39 | 22.78 |
| ABT Abbott Laboratories |
-0.36 0.33% |
109.56 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.14 0.14% |
101.66 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.84 0.26% |
325.03 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
9975 Summers Ridge Road, San Diego, CA, United States, 92121
858 552 1100
6500
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas C. Bryant | Chairman & CEO | 1958 |
| Mr. Robert J. Bujarski J.D. | Pres & COO | 1969 |
| Ms. Michelle A. Hodges | Gen. Counsel | 1960 |
| Dr. Werner Kroll Ph.D. | Sr. VP of R&D | 1957 |
| Mr. Joseph M. Busky CPA | Chief Financial Officer | 1968 |
| Ms. Louise Brandy | Chief Information Officer | NA |
| Mr. Patrick E. Klein | Chief Admin. Officer | NA |
| Ruben Argueta | Director of Investor Relations | NA |
| Mr. Michael S. Iskra | Chief Commercial Officer | 1970 |
| Phillip S. Askim | VP, Associate Gen. Counsel & Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.